Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
188Re-N-DEDC + Lipiodol
- Development stage
- Unknown
- Lead developer
- Bhabha Atomic Research Centre
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intra-arterial
01
Overview
188Re-N-DEDC + Lipiodol is an indigenously developed therapeutic radiopharmaceutical consisting of rhenium-188 (188Re) complexed with nitrido-diethyldithiocarbamate (N-DEDC) and formulated in Lipiodol (ethiodized oil). Developed by the Bhabha Atomic Research Centre (BARC) in India, it is designed for transarterial radionuclide therapy (TART) or transarterial radioembolization (TARE) of inoperable hepatocellular carcinoma (HCC), including cases with portal vein thrombosis (PVT). Rhenium-188 is a high-energy beta-emitting radioisotope (Eβmax = 2.1 MeV) with a half-life of 16.9 hours, which also emits a 155 keV gamma ray suitable for SPECT imaging and dosimetry. Lipiodol acts as a vehicle that is selectively retained within hypervascular liver tumors, allowing localized delivery of the therapeutic radiation while minimizing systemic toxicity.
- Other names
- 188Re-N-DEDC188Re-N-DEDC lipiodol188Re-N-DEDC/Lipiodol188ReN-DEDC/lipiodolRe-188 N(DEDC)2-LipiodolRe-188 N-DEDC lipiodolRe188 N-DEDC lipiodolRe 188 N-DEDC lipiodolRe-188 N-DEDC/lipiodolbis-(diethyldithiocarbamato) nitrido rhenium-188 lipiodolrhenium (188Re) nitrido bis(diethyldithiocarbamate) in lipiodolrhenium-188 nitrido diethyldithiocarbamate lipiodolrhenium188 nitrido diethyldithiocarbamate lipiodolrhenium 188 nitrido diethyldithiocarbamate lipiodolrhenium-188-N-DEDC lipiodolrhenium188-N-DEDC lipiodolrhenium 188-N-DEDC lipiodol
Beyond the preview
Go deeper on 188Re-N-DEDC + Lipiodol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 188Re-N-DEDC + Lipiodol.